DSM sells protective materials business for more than 1.4 billion euros
Financing in the global biotechnology field is still hot, and two Chinese companies are "loved" by capital
DSM expands production in China
The total amount of funds raised exceeds 100 billion Hong Kong dollars. What potential tracks are there for "18A" domestic biotechnology companies?
DSM Engineering Materials expands production capacity in China
Nature Biotechnology: Concealing the sky, putting on an "invisibility cloak" for bacteria, allowing
DSM expands production of high-performance materials in China
Professor Xu Yan's team of Jiangnan University Professor Nie Yao's research group published a computer-aided understanding in Biotechnology Advances
Nature Biotechnology Wei Wensheng's group reported an upgraded version of RNA editing technology: LEAPER 2.0
Shanghai Jiujiu Biotechnology Co., Ltd. appoints Mr. Tian Feng as CEO
Nature Biotechnology: Streamlining RNA Editing to Treat Genetic Diseases
Nature Biotechnology unveils a more efficient RNA editing technique
DSM's business performance is strong throughout the year
Guangzhou Nansha Biopharmaceutical Industrial Park to promote the development of biotechnology industry agglomeration
"Nature Biotechnology" RNA editing has reached a new level!
The 13th Five-Year Plan for Biotechnology Innovation: Over 4% of GDP
China Renaissance Capital's 2021 Annual Review of the Medical and Life Technology Industry|Pharmaceutical and Biotechnology
The State Food and Drug Administration notified the clinical trial of Hilite Biotechnology to have a cause-based inspection
Shanghai Zhenge Biotechnology Co., Ltd. raised US$100 million in Series C financing, led by Goldman Sachs and Sofina
Nature Biotechnology: Unprecedented new tool for cell tissue localization